Clinical Trial Update: Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype [Phase 4]

View source ↗

Summary

Phase IV multi-arm pharmacokinetics trial investigating CDK4/6 in healthy volunteers with CYP3A4*22 genotype has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cyp3a4 22-related Pharmacokinetics Considerations

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: CYP3A4*22 | Phase 4 | Status: WITHDRAWN